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Abstract 
Background:  
Epidemiological and genetic studies show an association between lipoprotein(a) (Lp(a)) 
plasma levels and cardiovascular risk in general population studies. However, in patients 
with established coronary heart disease (CHD), it remains less clear whether Lp(a) or LPA 
genetic variants predict long-term mortality. 
Methods:  
We analyzed the association between Lp(a) plasma concentrations and two LPA genetic 
variants (SNPs, rs10455872, rs3798220) with prevalent CHD phenotypes as well as long-
term outcomes in 3,313 participants of the Ludwigshafen Risk and Cardiovascular Health 
(LURIC) study (median follow-up 9·9 years). Association results for plasma Lp(a) 
concentrations were validated in five independent studies while genetic association findings 
were replicated through large scale collaborative analysis within the GENIUS-CHD 
consortium comprising 24 studies of patients with established CHD. 
Findings:  
While, we replicate the association of both plasma levels and SNPs prevalence with severity 
of CHD (tertile 3 of Lp(a) 1·44, 95% CI 1·14 to 1·83; any LPA SNP 1·88, 95 % CI 1·40 to 
2·53), Lp(a) levels were not associated with all-cause (tertile 3 of Lp(a) 0·95, 95 % CI 0·81 to 
1·11; any LPA SNP 1·10, 95% CI 0·92 to 1·31) or cardiovascular mortality (tertile 3 of Lp(a) 
0·99, 95 % CI 0·81 to 1·2; any LPA SNP 1·13, 95% CI 0·90 to 1·40) during follow-up of 
patients with established CHD. This finding was confirmed in five independent cohorts of 
10,195 CHD patients. Similarly, LPA SNPs were not associated with subsequent mortality 
once CHD had been established, a finding confirmed in a meta-analysis of 106,353 
participants with 19,332 events from the GENIUS-CHD consortium (all-cause mortality: LPA 
rs3798220 0·94, 95% CI 0·86 to 1·03; LPA rs10455872 0·95, 95% CI 0·90 to 1·03; 
cardiovascular mortality: LPA rs3798220 0·95, 95% CI 0·83 to 1·10; LPA rs10455872 0·96, 
95% CI 0·88 to 1·05). 
Interpretation:  
In patients with prevalent CHD, neither Lp(a) concentrations nor genetic variants associated 
with Lp(a) concentrations showed any association with subsequent mortality. These data 
suggest that Lp(a) as risk marker may be more useful in predicting first CHD event onset 
rather than progression to death after a CHD event. 
 
Funding: 
7th Framework Program (AtheroRemo and RiskyCAD, EU), INTERREG IV Oberrhein 
Program (A28), Deutsche Nierenstiftung, Else-Kroener Fresenius Foundation, Deutsche 
Stiftung für Herzforschung, Deutsche Forschungsgemeinschaft, Saarland University, 
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German Federal Ministry of Education and Research, Willy Robert Pitzer Foundation, 
Waldburg-Zeil Clinics Isny. 
Introduction  
Worldwide, cardiovascular disease (CVD) remains the leading cause of death1. Lipoprotein 
(a) (Lp(a)) is regarded as an emerging risk factor and potential therapeutic target, based on 
independent associations with atherosclerosis and CVD events in general population 
studies2,3. In a meta-analysis dated from the year 2000, the combined risk ratio for coronary 
heart disease (CHD) was 1.7 (95% confidence interval [CI] 1.4 to 1.9) for the top tertile of 
Lp(a) compared to the lowest tertile in 18 general population studies4. The Copenhagen City 
Heart Study arrived at a virtually identical risk estimate when comparing the highest to the 
lowest tertile of Lp(a), while reporting higher risks once Lp(a) exceeded the 90th percentile of 
its frequency distribution5. A more recent individual record-based meta-analysis of general 
population studies excluding participants with a history of CVD at baseline found a 
continuous, though modest relationship between Lp(a) and the incidence of CHD and stroke, 
with rates of CHD of 5.6 (95% confidence interval CI 5.4-5.9) and 4.4 (95% CI 4.2-4.6) per 
1000 person-years in the highest and in the lowest tertile of Lp(a), respectively6. 
 
Lp(a) is composed of a low-density lipoprotein (LDL)-like apolipoprotein B (ApoB)-containing 
core to which one copy of the apo(a) glycoprotein is attached by a disulfide bridge7-9. The 
physiological function of Lp(a) is not known, nor are the precise mechanisms of synthesis 
and catabolism. It has been suggested that Lp(a) is assembled on the surface membrane of 
hepatocytes10 and a number of cell surface receptors have been implicated in the catabolism 
of Lp(a)11. Lp(a) may have effects on the vascular tree similar to LDL, but has been 
postulated to be potentially more atherogenic due to specific pro-thrombotic effects3. The 
concentrations of Lp(a) in the circulation vary widely and are related to the number of kringle 
IV type 2 repeats and further sequence variants of the LPA gene12,13. Two common LPA 
variants, rs10455872 (intronic non-coding) and rs3798220 (missense variant Ile4399Met in 
the apo(a) protease-like domain), explain a substantial proportion of the variation of Lp(a) 
and have consistently been linked to the risk of incident myocardial infarction14,15.  
 
Unlike many other traditional risk factors for CHD, Lp(a) is difficult to modify by life-style 
changes3. PCSK9 inhibitors reduce Lp(a) by 20-30 %16, but are not yet routinely used for this 
purpose. Lipoprotein apheresis represents the only currently available approach to 
substantially lower Lp(a).  
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The relationship of elevated Lp(a) and future or recurrent cardiac events in patients with 
established CHD has been studied less extensively and so far appears weaker than in the 
general population. Further it may be modified by the LDL-cholesterol (LDL-C) 
concentration4,17,18. We therefore sought to examine systematically and at scale the 
association between Lp(a) and long-term mortality in patients with established CHD. 
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Methods 
LURIC study  
Between 1997 and 2000, the Ludwigshafen Risk and Cardiovascular Health (LURIC) study 
enrolled 3,316 German patients undergoing coronary angiography19. The study design and 
examinations at baseline have been described19. Written informed consent was obtained 
from all patients. Participants with acute illnesses other than acute coronary syndromes 
(ACS), such as malignancy or other chronic non-cardiac diseases within the past five years 
were excluded. Clinically stable patients (except for ACS) with available coronary angiogram 
data were enrolled. Information on death during follow-up was obtained from the local Public 
Health Departments. Cardiovascular mortality was defined as death due to fatal myocardial 
infarction, sudden cardiac death, death after cardiovascular intervention, stroke and other 
causes of death caused by cardiovascular diseases. 
The study was performed in accordance with the Declaration of Helsinki. An approval by the 
competent Ethics Committee (Ärztekammer Rhineland-Palatinate, Germany) was obtained. 
No patients were lost to follow-up.  
 
Validation cohorts 
Association findings for Lp(a) plasma levels and outcomes were validated in 10,195 
participants of the Homburg Cream and Sugar (HCS) study, the KAROLA study, the 
WENBIT/WECAC study, the PROSPER study and the ATHEROGENE study. For details on 
these cohorts please see appendix pages 2-3. 
 
GENIUS-CHD consortium 
Genetic association results for SNPs in the LPA locus and all-cause, as well as 
cardiovascular mortality were validated through a collaborative individual participant level 
analysis through the Genetics of Subsequent Coronary Heart Disease (GENIUS-CHD) 
consortium (www.genius-chd.com)20. This is a recently formed grouping of multiple 
international studies of patients with CHD (either stable disease or ACS), who have had 
blood or tissue samples stored for analysis or have genotyping data and have then been 
prospectively followed for subsequent events, such as death. Studies with available LPA 
SNP data from the wider GENIUS-CHD consortium were included, and are described in the 
appendix, page 1. 
 
 
 
Laboratory methods and procedures 
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In LURIC, blood sampling for measuring Lp(a) plasma levels (LPA Test, Rolf Greiner 
Biochimica, Flacht, Germany) was performed at the day of coronary angiography. Details for 
the other cohorts are described in the appendix pages 4-5. 
 
Statistical analysis 
Continuous data are presented as mean ± SD when normally distributed or as median and 
interquartile ranges for variables with skewed distribution. Categorical data are presented as 
percentages. Statistical differences between continuous variables were determined using 
one-way ANOVA, Kruskal–Wallis test, or chi-squared test for categorical variables. 
In LURIC, the association between Lp(a) plasma levels divided in tertiles as well as LPA 
SNP carrier status and all-cause as well as cardiovascular mortality was studied using Cox 
regression analyses with/without adjustment for age, sex, diabetes mellitus, systolic blood 
pressure, body mass index, smoking status, estimated glomerular filtration rate and LDL-
cholesterol.  
In sensitivity analyses we determined the association between Lp(a) plasma levels and 
mortality in LURIC in patients with/without statin treatment or divided into two groups using a 
cut-off at LDL-C of 130 mg/dL. Moreover, to examine the proportion of variance of Lp(a) 
caused by the LPA SNPs rs10455872 and rs3798220, η2 was calculated. 
Positive LPA SNP carrier status was defined as heterozygosity or homozygosity for the minor 
alleles of rs10455872 and/or rs3798220. In HCS, KAROLA, WENBIT/WECAC, PROSPER 
and ATHEROGENE, similar analyses were performed to examine the association between 
tertiles of Lp(a) and the composite cardiovascular end-points. Results of crude models as 
well as models adjusted for the following well-established cardiovascular risk factors, i.e. 
age, sex, diabetes mellitus, systolic blood pressure, body mass index, smoking status, 
estimated glomerular filtration rate, and LDL-cholesterol are reported. Hazard ratios (HRs) 
with 95% confidence intervals (CIs) are reported. 
To determine the association between tertiles of Lp(a) as well as LPA SNP carrier status and 
Friesinger score, generalized linear models were used to estimate the marginal (adjusted) 
means of Friesinger score. Adjustments were made for age, sex, diabetes mellitus, systolic 
blood pressure, body mass index, smoking status, estimated glomerular filtration rate and 
LDL-cholesterol.  
To analyze the association of the Lp(a) SNPs with cardiovascular outcome in the GENIUS-
CHD consortium, meta-analyses using log hazard ratios and their standard errors derived 
from unadjusted Cox regression models of the association of rs10455872 and rs3798220 
with fatal cardiovascular events and all-cause mortality from every cohort included were 
performed. Standard normal random effects meta-analysis was performed using the R-
package ‘metaplus’ (v 0.7-8). 
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Role of the funding source 
No role of the funding source. The corresponding author had full access to all data and the 
final responsibility to submit for publication. 
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Results 
3,313 participants of LURIC with Lp(a) measurements and genotyping were included in the 
present analyses. Baseline characteristics of these participants are shown in Table 1. 
Besides LDL-C and gender distribution, the prevalence of traditional cardiovascular risk 
factors such as age, reduced estimated glomerular filtration rate (eGFR), diabetes mellitus, 
smoking, or hypertension was not significantly different across tertiles of Lp(a) (tertile 1 ≤ 
10·0 mg/dL, tertile 2 10·1-26·0 mg/dL, tertile 3 > 26·0 mg/dL). The prevalence of CHD at 
baseline was 77·9 %. Following the strategy of a recent meta-analysis4, we divided Lp(a) in 
tertiles, thereby also minimizing the influence of different methodology used to measure 
Lp(a). In patients within the highest study-specific tertile of Lp(a), the prevalence of 
angiographically defined CHD was greater (81·9 % vs. 75·7 %) as compared to those in the 
lower tertile of Lp(a). 
 
LPA genetic variants and Lp(a) levels 
In LURIC, LPA SNP rs10455872 data were available in 3058 participants and LPA SNP 
rs3798220 data in 3286 participants. 524 participants (15·9 %) carried any LPA minor allele; 
ten participants carried a minor allele in LPA SNP rs10455872 and rs3798220. As previously 
reported14, in participants with Lp(a) plasma levels within the highest tertile, the frequencies 
of the minor alleles of rs10455872 and of rs3798220 were greater (P<0·001 each, Table 1). 
Notably, the number of copies of the minor allele for each LPA SNP was strongly associated 
with higher median Lp(a) plasma levels (P<0·001) in an almost linear fashion (appendix 
page 23). For each minor allele of the LPA SNPs carried, median Lp(a) was higher by 250 
%. 
 
Association with angiographic CHD 
We next determined the association of Lp(a) plasma levels and LPA SNPs with 
angiographically documented CHD (Figure 1A and appendix pages 6-7). Compared to 
patients with low Lp(a) (i.e. tertile 1), patients with Lp(a) within tertile 3 had a significantly 
higher risk for angiographic CHD (HR 1·44, 95% CI 1·14 to 1·83). Similar results were 
obtained for carriers of LPA risk variants, in whom odds for angiographic CHD was also 
significantly higher (OR 1·88, 95% CI 1·40 to 2·53), suggesting that Lp(a) causally impacts 
the development of CHD. 
 
We further examined the association between Lp(a) levels and LPA SNP carrier status with 
the Friesinger score as a measure for the severity of angiographic CHD (Figure 1B). Both, 
elevated Lp(a) plasma levels and LPA minor alleles were associated with higher Friesinger 
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scores (P<0·001 for tertile 3 of Lp(a) concentration and P<0·001 for LPA SNP carriers), 
indicating more severe CHD, which is in line with previous studies21,22.  
 
Association of Lp(a) levels with outcomes 
Next, we analyzed the association of elevated Lp(a) levels with subsequent all-cause and 
cardiovascular mortality. During a median follow-up of 9·9 years, 995 participants (30·0 %) of 
the LURIC study died, 622 due to CVD (18·8 % of all participants). Tertiles of Lp(a) were 
neither associated with all-cause nor cardiovascular mortality (Figure 2A and appendix, 
page 8). Adjustment for potential confounders did not change this observation. In additional 
analyses, this association was not modified (i.e. interact with) either LDL-C or statin 
treatment (appendix page 9).  
 
To validate these findings, we analyzed the association between Lp(a) plasma levels and 
subsequent cardiovascular mortality in five additional and independent cohorts (HCS, 
KAROLA, WENBIT/WECAC, PROSPER, ATHEROGENE) with 10,195 participants with 
prevalent CHD. Baseline characteristics of these studies are shown in appendix pages 10-
14. Notably, in all five contemporary cohorts of patients with stable CHD, tertiles of Lp(a) did 
not show any association with the composite cardiovascular end-point (events HCS: 218 
(42·4%), KAROLA: 263 (25·2%)) or cardiovascular mortality (events WENBIT/WECAC: 416 
(10·0%), PROSPER: 130 (7·0%), ATHEROGENE 230 (8·8%)) during follow-up (Figure 2B 
and appendix pages 15-19).  
 
Association of LPA genetic variants with outcomes 
We next examined the association between LPA SNPs and mortality in LURIC. Notably, we 
did not observe a significant association between either LPA SNP and all-cause or 
cardiovascular mortality during follow-up (Figure 2A and appendix page 20).  
 
To validate these findings still further we performed a meta-analysis of log hazard ratios and 
their standard errors in 24 studies from the recently formed GENIUS-CHD consortium 
comprising 106,353 participants with established CHD. Here we examined the association of 
both LPA risk variants and all-cause as well as cardiovascular mortality during follow-up. 
Baseline characteristics of the contributing studies of GENIUS-CHD are shown in appendix 
pages 21-22. Notably, both minor alleles of LPA (rs10455872 and of rs3798220) were not 
associated with increased all-cause mortality (Figure 3A+B) or cardiovascular mortality 
(Figure 3C+D).  
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Discussion 
In this study of patients with confirmed or suspected CHD, the concentration of Lp(a) at the 
time of recruitment and the number of minor alleles at two bi-allelic SNPs at the LPA locus 
were positively related to the presence and burden of CHD14,21,22. In contrast, we found that 
neither Lp(a) plasma concentrations nor LPA SNPs showed any association with 
cardiovascular or all-cause mortality during long-term follow-up in patients with established 
CHD, a finding we validated in 29 studies comprising 116,548 participants. 
 
For many years, Lp(a) has been known to be associated with risk for CHD, independent of 
traditional cardiovascular risk factors4-6,23-25. These findings mainly derive from studies on 
apparently healthy persons in the general population4-6,25 rather than from investigations of 
patients with established CHD. Genetic diversity at the LPA locus including rs10455872 and 
rs3798220 has been associated with the Lp(a) concentration in the plasma and with incident 
cardiovascular disease6,14. A recent study has shown that LPA KIV2 repeats as well as Lp(a) 
serum levels were associated with CHD prevalence26. A causal link between Lp(a) and 
atherosclerosis development is therefore likely and the current findings are completely in line 
with those reported previously.  
 
However, in the LURIC study and in the five independent validation cohorts of patients with 
established CHD and in 24 studies from the GENIUS-CHD consortium, we did not find any 
clear association of Lp(a) concentrations or LPA variants and subsequent long-term 
mortality. These findings at least raise the possibility that the association of Lp(a) with risk in 
patients with CHD is weaker than in healthy persons, which may be due to competing risks 
commonly prevalent in this patient population. In one of the earlier meta-analyses4, the risk 
ratio for CHD in general population based studies was 1.7 (95% CI 1·4 to 1·9) when the top 
tertile was compared with the lowest tertile of Lp(a), but only 1.3 (95 % CI 1·1 to 1·6) in nine 
studies of patients with pre-existing comorbidities (two studies in dialysis patients, one in 
diabetes mellitus, six in CHD). The latter was mainly driven by the contribution of the 
Scandinavian Simvastatin Survival Study (4S), which had recruited patients with severe 
hypercholesterolemia not representative of all CHD and accounted for three fourth of this 
evidence. Notably in 4S, total cholesterol was between 212 and 309 mg/dL, which is 
considerably higher than in LURIC or the studies of GENIUS-CHD, limiting generalization of 
the findings to cohorts with lower total cholesterol. Only one of the eight remaining studies 
reported a significant association between Lp(a) and incident CHD4. Another, more recent 
publication examining Lp(a) in established CHD has also indicated a modest, non-significant 
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relationship between Lp(a) and future events in studies with mean LDL-C below 130 mg/dL 
at baseline, and a stronger association in patients with LDL-C greater than 130 mg/dL17. 
 
Taken together, the association between Lp(a) and cardiovascular events may therefore be 
modified by LDL-C, and, beyond this, also by the high levels of statin use. While we were not 
able to detect such interactions in the present analyses, it is worth noting that baseline LDL-
C in LURIC was 117±34 mg/dL and on average 130±38 mg/dL in the studies of the GENIUS-
CHD consortium and as such we were unable to examine the association of Lp(a) with 
outcomes at very high levels of LDL-C. Adjustments for other potential confounders 
investigated at baseline also did not modify our findings, although we were unable to account 
for other factors that may have changed during follow-up such as LDL-C. However, 
considering the poor adherence with statins in Germany, we suspect the impact of time 
dependent changes of LDL-C is unlikely, at least in German cohorts contributing to our 
analysis27. 
 
There are other limitations that need consideration. Firstly, Lp(a) plasma levels in LURIC and 
in the validation cohorts have been measured using different methods. To exclude biases 
caused by different calibrations of these assays, all risk estimates were calculated for tertiles 
of Lp(a) calculated within each cohort. Nevertheless, we cannot entirely exclude the 
possibility that Lp(a) plasma levels were altered by the initial cardiovascular event itself or by 
changes during follow-up. Secondly, the current study has focused only on all-cause and 
cardiovascular mortality, while others have combined a range of fatal and non-fatal 
cardiovascular events4-6,17. We have preferred this strategy because it is arguably robust 
against differences between studies and changes over time in the definition and adjudication 
of non-fatal events28. This could have reduced our statistical power due to fewer events and 
meant we missed potentially very small effect sizes. The possibility of a type 2 error remains 
although with the sample size afforded by our multiple replication cohorts we anticipate this 
risk is minimal. Although we did not find evidence for an effect of Lp(a) above 50 mg/dL (not 
shown) beyond which the recent ESC and EAS guideline considers risk significant29, we 
cannot rule out that extreme concentrations would still have an impact. Finally, we cannot 
currently exclude the impact of Lp(a) levels or genetic variants on risk of subsequent non-
fatal events in contrast to fatal events given that such differences have been described for 
other risk factors30. Ischemic and/or thrombotic events, fatal and non-fatal, might be more 
specifically related to Lp(a) than the totality of CVD deaths. These will require further study 
as outcome data emerges, particularly since Lp(a) levels appeared to associate similarly with 
fatal CHD and non-fatal MI in prior analyses in patients without CHD6. 
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To the best of our knowledge, this is the largest study in which the association of Lp(a) levels 
and SNPs at the LPA locus with outcomes in patients with established CHD has been 
examined simultaneously. Our results, and others show that Lp(a) levels and LPA SNPs 
promote early development of atherosclerosis and associate with greater angiographic 
severity of CHD. Further, it has been shown that patients with established CHD who carry 
Lp(a) increasing SNPs are more likely to have earlier CHD onset and have greater 
susceptibility to atherosclerotic manifestations outside of the coronary tree21, supporting a 
role of Lp(a) in atherosclerosis progression. The lack of association of Lp(a) with CVD fatality 
in established CHD is thus a surprising finding that we do not have a final explanation for. 
Among the possible explanations would be index event or survival biases. These cannot be 
fully excluded, but are unlikely to have impacted our findings significantly as the minor allele 
frequencies of the LPA SNPs were identical to those reported in the control populations 
including the PROCARDIS cohort and other cohorts14 and given the lack of imbalances of 
patients characteristics across genotypes. It is important to note that although Lp(a) 
concentrations would not be useful for predicting mortality, CHD patients with high Lp(a) 
could still benefit from Lp(a) lowering, as it might attenuate disease progression. 
 
Screening for elevated Lp(a) has been recommended in persons at intermediate or high risk 
of CVD or CHD according to conventional criteria3. Given the broad evidence in favor of 
Lp(a) as a marker of risk in clinically healthy persons3,24 , our data would indicate that it might 
be more rewarding to integrate Lp(a) into risk stratification in primary rather than in 
secondary prevention. We acknowledge, however, that markedly increased Lp(a) plasma 
concentrations in patients with established CHD may be helpful to trigger an intensive 
screening of family members to improve early preventive measures for the carriers.  
 
Importantly, interventions to lower Lp(a) are scarce. While drug therapies may eventually be 
used for lowering Lp(a), it has to be determined to which extent Lp(a) lowering by PCSK9 
inhibiting antibodies affects cardiovascular outcomes besides their strong effect on lowering 
of LDL-C16. More specific therapies targeting Lp(a) directly such as anti-sense 
oligonucleotides are in development and testing stages and will shed further light on the 
value of reducing Lp(a) in the future31. 
 
In conclusion, we found that while plasma Lp(a) levels and genetic variants that strongly 
determine Lp(a) levels are associated with CHD burden and severity, however, neither 
predict risk of future subsequent cardiovascular or total mortality among participants with 
established CHD. While the discrepancy with findings in general populations where Lp(a) 
increases risk of a first CHD event requires further investigation, these data suggest that use 
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of Lp(a) as a risk marker may be more useful in predicting first CHD event onset rather than 
progression to death after a CHD event. 
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Research in context 
Evidence before this study 
Plasma Lp(a) is a recognized emerging risk factor for coronary heart disease (CHD). We 
performed a systematic search in MEDLINE using the terms ‘lipoprotein(a)’ or ‘lp(a)’ to 
identify studies reporting on the association between Lp(a) and cardiovascular risk. Last 
search has been performed on May 15, 2016. Several studies show a clear association 
between elevated Lp(a) plasma levels and an increased risk for atherosclerotic CVD in 
general populations. However, such an association is weak or absent in fewer and 
underpowered studies of patients with established CHD. Given that Lp(a) plasma levels are 
genetically determined by two SNPs in LPA loci (rs10455872 and rs3798220), larger 
epidemiologic and genetic association studies are now feasible to explore the role of Lp(a) in 
patients with CHD. Importantly, therapies for reducing Lp(a) are also emerging. Thus, a 
greater understanding of the role of Lp(a) in patients with established CHD would aid its use 
as a risk stratification biomarker and treatment target in this population.  
 
Added value of this study 
Our study examined the association between Lp(a) concentrations and two common variants 
at the LPA locus with (1) the prevalence and severity of CHD and (2) mortality during long-
term follow-up in patients with established CHD. In 29 independent cohorts consisting of 
116,548 participants during long-term follow-up, neither Lp(a) concentrations nor LPA 
genetic variants were associated with cardiovascular or all-cause mortality during follow-up.  
 
Implications of all the available evidence 
While the observational data for measuring Lp(a) for risk stratification in general populations 
is robust, our findings raise questions about the value of doing this in patients with 
established CHD. The reasons for the discrepancy require further detailed study. Importantly, 
therapies to reduce Lp(a) are emerging such as PCSK9 inhibitors and antisense agents.  
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Figure legends 
Figure 1: (A) Association between tertiles of Lp(a) or carrier status of LPA SNPs, 
respectively, and coronary heart disease as determined by logistic regression analyses. 
Multivariate analyses were adjusted for age, sex, diabetes, systolic blood pressure, body 
mass index, smoking status, estimated glomerular filtration rate, LDL-C, and lipid-lowering 
therapy. (B) Marginal means (95 % CI) of the severity of coronary disease (Friesinger score) 
according to tertiles of Lp(a) or LPA SNP carrier status. Analyses were adjusted for age, sex, 
diabetes, systolic blood pressure, body mass index, smoking status, estimated glomerular 
filtration rate, LDL-C, and lipid-lowering therapy. 
 
Figure 2: (A) Association between tertiles of Lp(a) as well as LPA SNP carrier status and all-
cause as wells as cardiovascular mortality in participants of the LURIC study as determined 
by Cox regression analyses adjusted for age, sex, diabetes, systolic blood pressure, body 
mass index, smoking status, estimated glomerular filtration rate, LDL-C, and lipid-lowering 
therapy. (B) Association between tertiles of Lp(a) and composite cardiovascular end-point 
(HCS and KAROLA) and cardiovascular mortality (WENBIT/WECAC, PROSPER and 
ATHEROGENE) as determined by Cox regression analyses. Multivariate analyses were 
adjusted for age, sex, diabetes, systolic blood pressure, body mass index, smoking status, 
estimated glomerular filtration rate, and LDL-C. 
 
Figure 3: Forest plot of risk ratios for all-cause (A) and (B) as well as cardiovascular mortality 
(C) and (D) according to LPA SNPs rs3798220 (A) and (C) as well as rs10455872 (B) and 
(D) in studies of GENIUS-CHD consortium. Markers represent point estimates of risk ratios; 
marker size represents study weight in random-effect meta-analysis. Horizontal bars indicate 
95% confidence intervals. 
 
 
Table 1 
Baseline characteristics of the LURIC cohort, overall and stratified according to tertiles of Lp(a) 
 
 Overall 
 
(n=3313) 
Lp(a) 
Tertile 1 
≤ 10·0 mg/dL 
(n=1146) 
Lp(a) 
Tertile 2 
10·1-26·0 
mg/dL 
(n=1065) 
Lp(a) 
Tertile 3 
>26·0 mg/dL 
(n=1102) 
P* 
Age 62·7±10·6 62·8±10·7 62·8±10·7 62·4±10·4 0·445 
Sex      
   Male 2308 (69·7%) 842 (73·5%) 735 (69·0%) 731 (66·3%) 0·001 
   Female 1005 (30·3%) 304 (26·5%) 330 (31·0%) 371 (33·7%) 0·001 
BMI (kg/m2) 27·5±4·1 27·5±4·1 27·7±4·2 27·2±3·9 0·066 
Systolic blood pressure (mmHg) 141±24 142±23 140±24 141±24 0·184 
Lp(a) (mg/dL) 16·0 (31·0) 5·0 (6·4) 16·0 (7·1) 58·0 (44·7) <0·001 
Any LPA SNP minor allele& 524 (15·9%) 73 (6·4%) 81 (7·7%) 370 (34·0%) <0·001 
LPA SNP rs10455872$ A/G 399 (13·1%) 56 (5·2%) 63 (6·4%) 280 (27·8%) <0·001 
LPA SNP rs10455872$ G/G 10 (0·3%) 0 1 (0·1%) 9 (0·9%) <0·001 
LPA SNP rs3798220§ T/C 124 (3·8%) 17 (1·5%) 19 (1·8%) 88 (8·1%) <0·001 
LPA SNP rs3798220§ C/C 1 (<0·1%) 0 0 1 (0·1%) <0·001 
Total cholesterol (mg/dL) 192±39 189±39 191±38 197±40 <0·001 
Triglycerides (mg/dL)  173±118 179±136 173±115 167±99 0·089 
HDL-C (mg/dL) 39±11 38±11 39±11 39±10 0·037 
LDL-C (mg/dL) 117±34 112±34 116±33 122±36 <0·001 
VLDL-C (mg/dL) 37±26 39±30 36±26 36±24 0·002 
Apolipoprotein B (mg/dL) 104±25 103±24 103±24 107±25 <0·001 
Glycated hemoglobin (%) 6·3±1·2 6·3±1·4 6·3±1·2 6·3±1·2 0·203 
eGFR CKD-EPI (ml/min/1·73m2) 81·7±20·1 82·1±20·7 81·5±20·1 81·4±19·6 0·602 
hsCRP (mg/L) 3·4 (7·3) 3·6 (8·4) 3·4 (7·1) 3·2 (6·3) 0·037 
IL-6 (ng/L) 3·2 (4·3) 3·3 (4·8) 3·2 (4·2) 3·2 (4·1) 0·235 
Fibrinogen (mg/dL) 377 (132) 370 (142) 380 (128) 381 (124) 0·619 
Friesinger Score 5·4±3·9 5·1±3·9 5·2±4·0 5·9±3·8 <0·001 
Coronary artery disease  2580 (77·9%) 867 (75·7%) 810 (76·1%) 903 (81·9%) <0·001 
Previous myocardial infarction  1365 (41·2%) 446 (38·9%) 448 (42·1%) 471 (42·7%) 0·144 
Diabetes mellitus  1322 (39·9%) 467 (40·8%) 440 (41·3%) 415 (37·7%) 0·170 
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Lipid lowering therapy  1607 (48·5%) 489 (42·7%) 529 (49·7%) 589 (53·4%) <0·001 
Smoking  2120 (64·0%) 741 (64·7%) 681 (63·9%) 698 (63·3%) 0·808 
Hypertension 2409 (72·7%) 826 (72·1%) 762 (71·5%) 821 (74·5%) 0·255 
Total deaths (all-cause) 994 (30·0%) 361 (31·5%) 322 (30·2%) 311 (28·2%) 0·233 
Cardiovascular deaths  621 (18·9%) 232 (20·4%) 186 (17·6%) 203 (18·5%) 0·129 
 
Values are presented as mean (SD), median (IQR) or number (%). BMI=body mass index. HDL=high-density lipoprotein. LDL=low-density 
lipoprotein. VLDL=very low-density lipoprotein. Lp(a)=lipoprotein(a). IL-6=interleukin-6. eGFR=estimated glomerular filtration rate. hsCRP=high 
sensitivity C-reactive protein.  
* Comparison between tertiles of Lp(a). p < 0·05 was considered significant. $ LPA SNP rs10455872 data were available in 3058 participants. § 5 
LPA SNP rs3798220 data were available in 3286 participants. & Ten participants carried a minor allele in LPA SNP rs10455872 and rs3798220. 
Any LPA SNP minor allele information is available in 3287 participants. In 23 participants, no information on LPA SNPs is available. 
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